ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31

Actinium Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$1.32+0.19 (+16.81%)

Close on Oct 19, 2026

Market cap: $41.46M
P/E (TTM): 3.7
Dividend yield: –

Actinium Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Cash & Equivalents	48	73	77	110	78	64	9.69	14	18	21	26	6.71	5.53	5.62	5.70	0.20	0.00	–	–	–
Cash & Short-Term Investments	48	73	77	110	78	64	9.69	14	18	21	26	6.71	5.53	5.62	5.70	0.20	0.00	–	–	–
Inventory	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–
Prepaid Expenses & Other	1.38	1.60	1.59	1.64	1.48	1.32	0.79	0.62	0.44	1.84	0.80	0.70	0.22	0.17	0.01	–	–	–	–	–
Other Current Assets	0.17	0.36	0.23	0.07	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Assets	49	75	78	111	80	65	10	14	18	22	26	7.41	5.75	5.79	6.20	0.00	–	–	–	–
Property, Plant & Equipment	0.30	0.36	0.55	0.60	0.34	0.31	0.11	0.12	0.06	0.09	0.11	0.13	0.01	0.00	0.00	0	–	–	–	–
Gross Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	–	–	0.02	0.16	0.16	0	–	–	–	–
Accumulated Depreciation	-1.06	-0.89	-0.69	-0.49	-0.34	-0.29	-0.24	-0.27	-0.22	-0.17	-0.09	-0.04	0.00	-0.15	-0.15	0	–	–	–	–
Operating Lease Right-of-Use Assets	1.75	1.69	2.29	2.34	0.24	0.58	0.81	–	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	–	–	–	0.10	–	–	–	–	–	–	–	–	–	–
Total Assets	52	77	81	114	80	66	12	15	18	23	27	7.57	5.77	5.79	6.20	0.00	–	–	–	–
Accounts Payable	7.25	7.57	7.95	–	–	4.34	4.60	5.81	4.65	4.19	1.47	2.28	0.38	–	0.00	0.01	–	–	–	–
Accrued Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	0.00	–	–	–	–
Current Portion of Leases	0.71	0.57	0.53	0.49	0.25	0.34	0.29	–	–	–	–	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–
Deferred Revenue (Current)	–	–	–	–	1.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Current Liabilities	–	–	–	–	1.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	7.97	8.15	8.49	11	6.84	4.77	5.34	6.06	4.67	4.52	4.61	9.49	7.33	4.64	5.21	0.04	–	–	–	–
Long-Term Debt	–	–	–	–	–	–	0.90	–	–	–	–	–	–	–	–	–	–	–	–	–
Long-Term Leases	0.97	0.98	1.55	2.08	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	1.68	1.55	2.08	2.58	0.25	0.34	0.29	–	–	–	–	–	–	–	–	–	–	2.21	–	–
Total Liabilities	44	44	45	48	6.84	5.08	6.03	6.08	4.67	4.52	4.61	9.49	7.33	4.64	0.08	0.09	–	–	–	–
Total Debt	–	–	–	–	–	–	0.90	–	–	–	–	–	–	–	–	–	–	–	–	–
Preferred Stock	–	–	–	–	–	–	–	–	–	0	–	–	–	–	0	0	–	–	–	–
Common Stock	0.03	0.03	0.03	0.03	0.02	0.02	0.01	0.12	0.08	0.06	0.04	0.03	0.02	0.02	0.14	0.11	–	–	–	–
Additional Paid-In Capital	418	409	374	355	329	292	214	196	177	155	134	89	65	57	48	0.06	–	–	–	–
Retained Earnings	-410	-376	-338	-289	-256	-231	-209	-187	-163	-137	-112	-91	-67	56	-0.26	-0.27	–	–	–	–
Comprehensive Income & Other	-0.02	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	7.83	33	36	66	74	61	5.64	8.81	14	18	22	-1.92	-1.56	1.15	0.99	0.40	0.85	4.16	3.46	1.82
Total Equity	7.83	33	36	66	74	61	5.64	8.81	14	18	22	-1.92	-1.56	1.15	0.99	0.40	0.85	4.16	3.46	1.82
Total Liabilities & Equity	52	77	81	114	80	66	12	15	18	23	27	7.57	5.77	5.79	6.20	0.00	–	–	–	–
Shares Outstanding(shares)	31	31	28	26	22	18	5.49	3.86	2.67	1.86	1.47	1.00	0.82	0.71	0.46	0.03	–	–	–	–
Deposits	–	–	–	–	–	–	–	0.39	0.39	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: 10617.8%
Net margin: 12564.4%
Return on equity, FY2025: -167.0%

Financial strength

Current ratio: 4.08
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 393.9%

Valuation

P/E ratio: 3.7
Price to sales: 460.63
Price to book: 1.37
Dividend yield: –